drugset
drugset / Trial / NCT04544813

A Study of JNJ-77474462 in Healthy Participants

NCT04544813 ↗

Phase 1 Completed 78 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to assess the pharmacokinetics (PK) of JNJ-77474462 after single subcutaneous (SC) or intravenous (IV) administrations and the effect of formulation concentrations on PK of JNJ-77474462 in healthy participants.

Timeline

Start
2020-10-13
Primary completion
2021-05-30
Completion
2021-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Bermekimab Monoclonal antibody — Subcutaneous
Comparator Anakinra Protein / enzyme biologic 100 mg Subcutaneous

Indications

No indication recorded.